Patient Experience and Preferences for Treatments in Atopic Dermatitis
10 affiliations
- 1Forefront Dermatology, Viriginia Beach, VA USA
- 2Department of Dermatology, University of Illinois-Chicago, Chicago, IL USA
- 3Infinity Dermatology, New York, NY USA
- 4Department of Dermatology, San Francisco School of Medicine, University of California, San Francisco, CA USA
- 5Synergy Dermatology, San Francisco, CA USA
- 6Castle Biosciences, Inc, 1500 W. Parkwood Dr., 4th Floor, Friendswood, TX 77546 USA
- 7Baylor Scott & White Health System, Dallas, TX USA
- 8Bare Dermatology, Dallas, TX USA
- 9Department of Dermatology, Medical Faculty Associates, George Washington University, Washington, DC USA
- 10Northwestern University Feinberg School of Medicine, Chicago, IL USA
Abstract
Introduction: Although type 2 inflammatory pathway dysfunction is a hallmark of atopic dermatitis (AD), disease symptoms in many patients are also driven by other immune/inflammatory pathway dysfunctions, all of which lead to varied treatment response profiles of targeted systemic therapies for individual patients. Adding complexity to the process of identifying which systemic therapy to prescribe for an individual patient is that these treatments have varied safety profiles, routes of administration, monitoring requirements, and costs—all of which are reviewed during today’s shared decision-making discussions.
Methods: This patient assessment study aimed to better understand patients' attitudes toward contemporary AD treatments, their experiences, and their perceptions of a molecular test to predict treatment response. A 32-question assessment tool, deemed eligible for IRB exemption, was made available to any attendees with AD at the 2024 Eczema Expo who wished to complete it.
Results: Regarding treatment objectives, results indicated the top three factors most important to respondents (n = 40) were itch control (70%), skin clearance (58%), and safety/side effects (50%). For respondents switching from their initial topical therapy due to lack of efficacy (n = 37), 38% switched to a systemic drug. Among respondents who had used targeted systemics (n = 22), 18% switched systemics, 4.5% added another systemic, 32% added topicals, and 45% did not modify their initial systemic treatment. The top two reasons for switching systemics or adding a topical treatment to their systemic were insufficient skin clearance and itch control. Of respondents open to taking a new systemic therapy, 94% showed interest in a test that would inform them about which targeted systemic therapy would work best for them.
Conclusion: These findings highlight a clinical need for personalized therapeutic guidance in AD to improve patient care and treatment satisfaction.
Related
- Subcorneal Pustular Dermatosis as a Complication of Upadacitinib Therapy in a Patient with Atopic Dermatitis: A Case Report
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study
- 48-Week Real-World Atopic Dermatitis Study on Minimal Disease Activity, Associated Factors, and Agreement Between Clinician- and Patient-Reported Outcomes
- Topical Calcium Thioglycolate for Severe Plantar Hyperkeratosis in Atopic Dermatitis: A Case Report
BibTeX
@article{dasilva2026patient,
title = {{Patient Experience and Preferences for Treatments in Atopic Dermatitis}},
author = {Diego Ruiz Dasilva and Joshua Burshtein and Jeffrey Weinberg and John Koo and Tina Bhutani-Jacques and Lenka V. Hurton and Aaron S. Farberg and Adam Friedman and Peter A. Lio},
journal = {Dermatology and Therapy},
year = {2026},
month = sep,
doi = {10.1007/s13555-026-01912-w},
url = {https://doi.org/10.1007/s13555-026-01912-w},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Patient Experience and Preferences for Treatments in Atopic Dermatitis
AU - Diego Ruiz Dasilva
AU - Joshua Burshtein
AU - Jeffrey Weinberg
AU - John Koo
AU - Tina Bhutani-Jacques
AU - Lenka V. Hurton
AU - Aaron S. Farberg
AU - Adam Friedman
AU - Peter A. Lio
PY - 2026
DA - 2026/09/01
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01912-w
UR - https://doi.org/10.1007/s13555-026-01912-w
AB - Introduction: Although type 2 inflammatory pathway dysfunction is a hallmark of atopic dermatitis (AD), disease symptoms in many patients are also driven by other immune/inflammatory pathway dysfunctions, all of which lead to varied treatment response profiles of targeted systemic therapies for individual patients. Adding complexity to the process of identifying which systemic therapy to prescribe for an individual patient is that these treatments have varied safety profiles, routes of administration, monitoring requirements, and costs—all of which are reviewed during today’s shared decision-making discussions. Methods: This patient assessment study aimed to better understand patients' attitudes toward contemporary AD treatments, their experiences, and their perceptions of a molecular test to predict treatment response. A 32-question assessment tool, deemed eligible for IRB exemption, was made available to any attendees with AD at the 2024 Eczema Expo who wished to complete it. Results: Regarding treatment objectives, results indicated the top three factors most important to respondents (n = 40) were itch control (70%), skin clearance (58%), and safety/side effects (50%). For respondents switching from their initial topical therapy due to lack of efficacy (n = 37), 38% switched to a systemic drug. Among respondents who had used targeted systemics (n = 22), 18% switched systemics, 4.5% added another systemic, 32% added topicals, and 45% did not modify their initial systemic treatment. The top two reasons for switching systemics or adding a topical treatment to their systemic were insufficient skin clearance and itch control. Of respondents open to taking a new systemic therapy, 94% showed interest in a test that would inform them about which targeted systemic therapy would work best for them. Conclusion: These findings highlight a clinical need for personalized therapeutic guidance in AD to improve patient care and treatment satisfaction.
SN - 2193-8210
SN - 2190-9172
ER -